Streetbeat News

Stock Prices

OXBR

Oxbridge Re Holdings (NASDAQ:OXBR) reported a significant decrease in its Q1 earnings per share (EPS) to $(0.15) from $0.02 YoY, and a sharp decline in sales to $(125.00K) from $545.00K YoY, marking a substantial downturn in its financial performance.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:48 pm

IOSP

Innospec reported Q1 2024 adjusted EPS of $1.75, surpassing the $1.64 estimate, but its sales of $500.2M fell short of the $504.133M forecast, marking a 1.84% year-over-year decrease.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:47 pm

COLL

Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 2024 adjusted EPS of $1.45, surpassing the $0.73 estimate, marking a 98.63% beat and a 9.85% increase from last year's $1.32. However, their Q1 sales of $144.923M fell short of the $146.853M estimate by 1.31%, only slightly up by 0.11% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:46 pm

GRPN

Groupon has projected its FY24 revenue to be between $489M and $515M, which is below the estimated $522.851M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:46 pm

GRPN

Groupon has projected its Q2 2024 revenue to be between $116 million and $122 million, which is below the estimated $122.647 million. This forecast suggests a potential shortfall in revenue expectations for the company.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:46 pm

PFE

Pfizer (NYSE:PFE) has seen a notable increase in options activity, with a bearish sentiment prevailing among investors. Analysis of 27 trades reveals 29% bullish and 59% bearish positions, with significant activity in puts and calls indicating a price band focus between $15.0 and $32.5. The market's attention on Pfizer's options suggests liquidity and interest at these strike prices. Pfizer, a leading pharmaceutical company with annual sales nearing $50 billion, has its stock price currently up 1.15% at $28.17. Analyst ratings over the past month average a target price of $38.75, with varying opinions from firms like Cantor Fitzgerald and Morgan Stanley.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 8:46 pm

CARG

CarGurus forecasts Q2 total revenue to be between $202M-$222M, slightly below the estimated $224.504M, with an adjusted EPS of $0.29-$0.34, aligning with the estimated $0.30.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:45 pm

NGVC

Natural Grocers (NGVC) reported a 34.62% increase in Q2 2024 GAAP EPS to $0.35 from $0.26 YoY, with sales rising 8.77% to $308.092M from $283.245M YoY.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:45 pm

AMPS

Altus Power (NYSE:AMPS) reported Q1 2024 earnings of $0.05 per share, surpassing the $(0.08) estimate, marking a 162.5% beat and a 66.67% increase from last year's $0.03. Sales reached $40.659M, exceeding the $39.920M estimate by 1.85% and showing a 38.40% increase from the previous year's $29.378M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:45 pm

DNA

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q1 2024 earnings with a GAAP EPS of $(0.08), surpassing the $(0.09) estimate. However, their sales of $38M fell short of the $46.044M estimate, marking a 52.91% decrease from the previous year's $80.702M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:43 pm